# SEIR MODEL WITH A VACCINATION PARAMETER USING COVID-19 AS A CASE STUDY

Edet Uduak Anietie<sup>1</sup> and Etukudo Ini-Obong<sup>2</sup>.

# <sup>1</sup>Department of Mathematics, University of Uyo, Uyo, Nigeria. <sup>2</sup>Department of Economics, University of Uyo, Nigeria.

# Abstract

The SEIR mathematical model with a vaccination parameter is formulated to study the spread of COVID-19. The equilibrium points of the system of differential equations are obtained. The local and global stabilities of the disease-free and endemic equilibria are presented. The basic reproduction number of the model is obtained. The parameters used in the model are estimated. The system of differential equations representing the model is solved numerically using the scilab software application. The result of the simulation shows that in the long term, the presence of a vaccination parameter causes the disease to converge to the disease-free equilibrium for any value of the basic reproduction number.

Keywords: Stability, SEIR Model, Vaccination parameter, COVID-19, Scilab

# 1. Introduction

A COVID-19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). The COVID-19 vaccines are widely credited for their role in reducing the severity and death caused by COVID-19 [1]. Many countries have implemented phased distribution plans that prioritize those at highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers [2].

As of 1 February 2022, 10.1 billion doses of COVID-19 vaccines have been administered worldwide based on official reports from national public health agencies [3]. By December 2020, more than 10 billion vaccine doses had been preordered by countries, [4] with about half of the doses purchased by high income countries comprising 14% of the world's population [5].

There are several authors [6-11] who have recently developed mathematical models to study the effect of vaccination strategies in the control of the dynamics of COVID-19. In this article, we have formulated a simple mathematical model to study the effect of vaccination on the spread of COVID-19 in a population. We present results for the stability analysis of the steady states of the model and we carry out a numerical simulation on the model.

# 2. Materials and Methods

# **SEIR Model Assumptions:**

- 1. The population under consideration is divided into four disjoint classes which change with time (t). These classes are: The Susceptible class, denoted by (S), the Exposed class, denoted by (E), the Infective class, denoted by (I), and the Removed class (which comprises of individuals removed from the population by either death, recovery or vaccination), denoted by (R).
- 2. The population under consideration has a constant size P and is sufficiently large, so that the sizes of each class can be considered as continuous variables
- 3. The population is homogeneously mixing. Individuals make contact at random and do not mix mostly in a smaller subgroup.
- 4. We assume that there is no immigration or emigration

Corresponding Author: Edet U.A., Email: uduakaedet@uniuyo.edu.ng, Tel: +2347035031234

- 5. The model includes vital dynamics (births and deaths). We assume that the births and deaths occur at equal rates and all newborns are susceptible.
- 6. Individuals are removed by death from each class at a rate proportional to the class size with proportionality constant  $\gamma$  (the birth or death rate).
- 7. In the susceptible class *S*, a susceptible person becomes infected and moves into the Exposed class at a rate proportional to the product *SI* with proportionality constant  $\frac{\tau}{P}$ . The contact rate  $\tau$  (rate of infection) is the average number of adequate contacts per infective per unit time.
- 8. From the exposed class (*E*), an individual becomes infective and moves into the infective class at a rate proportional to the class size *E* with proportionality constant  $\delta$ .
- 9. Individuals recover and leave the infective class (I) at rates proportional to the class size I, with proportionality constants  $\alpha_1$  and  $\alpha_2$ . Individuals that don't survive the disease die and leave the class (I) with proportionality constant  $\mu$ .
- 10. Individuals from the susceptible class (S) who are vaccinated, move into the removed class (R) at a rate proportional to the class size S, with proportionality constant  $\theta$ .

#### **Parameters of the Model:**

- 1.  $\gamma$ : Natural mortality rate (Birth or Death rate). The time unit is set at day. The constant natural mortality rate is assumed to be inversely proportional to the global average life expectancy of birth. This is taken to be approximately 72 years [12].  $\mu = \frac{1}{26280} = 0.000038 day^{-1}$ .
- 2.  $\tau$ : The rate of infection  $\tau = (number of new cases over a time period)/ (total population at risk during the same time period).$
- 3.  $\delta$ : Transition rate from Exposed class to Infective class (We assume it is inversely proportional to the latent period of the disease). In [13], it is reported that the median time prior to symptom onset (latent period), is 3 days. If we take the latent period to be 3 days, (range 1-24 days), we get;  $\delta = \frac{1}{2} = 0.33 day^{-1}$ .
- 4.  $\alpha_1$ : Recovery rate for patients with mild symptoms. We assume it is inversely proportional to the average period of infectivity (the time between COVID-19 infection and recovery for people with mild symptoms). If we take the average recovery time for people with mild symptoms to be 2 weeks [14], we get;

$$\alpha_1 = \frac{1}{14} = 0.07143 day^{-1}$$

5.  $\alpha_2$ : Recovery rate for patients with more severe symptoms. We assume it is inversely proportional to the average period of infectivity (the time between COVID-19 infection and recovery for people with severe symptoms). If we take the average recovery time for people with severe symptoms to be 4.5 weeks [14], we get:

$$\alpha_2 = \frac{1}{31.5} = 0.031746$$

- 6.  $\mu$ : Disease-related death rate  $\mu$  = (number of deaths over a defined period of time) / (confirmed cases diagnosed within that time period).
- 7.  $\theta$ : The rate at which individuals from the susceptible class are removed by vaccination. We assume that it is inversely proportional to the average duration of the immunity conferred by the COVID-19 vaccine. If we take the average duration of immunity to be six months [15], we get:  $\theta = \frac{1}{180} \approx 0.0056 day^{-1}$

The dynamics of the disease is represented by the following system of differential equations:

$$\frac{dS}{dt} = \gamma P - \frac{\tau}{P} SI - \gamma S - \theta S$$

$$\frac{dE}{dt} = \frac{\tau}{P} SI - (\delta + \gamma)E$$
(1)
$$\frac{dI}{dt} = \delta E - (\alpha_1 + \alpha_2 + \mu + \gamma)I$$

$$\frac{dR}{dt} = (\alpha_1 + \alpha_2 + \mu + \gamma)I + \theta S - \gamma R$$

$$\gamma, \delta, \tau, \mu, \alpha_1, \alpha_2, \theta > 0$$
S, E, I, R > 0
Equilibria of the Model: From Eq. (1) we get the following;
$$\gamma P - \frac{\tau}{P} S\overline{I} - (\gamma + \theta)S = 0$$
(2)
$$\frac{\tau}{P} S\overline{I} - (\delta + \gamma)\overline{E} = 0$$
(3)

$$\begin{split} \delta \bar{E} &- (\alpha_1 + \alpha_2 + \mu + \gamma) \bar{I} & (4) \\ (\alpha_1 + \alpha_2 + \mu + \gamma) \bar{I} + \theta \bar{S} - \gamma \bar{R} &= 0 \end{split} \tag{5}$$

From Eq. (3), we get;  

$$\overline{E} = \frac{(\alpha_1 + \alpha_2 + \mu + \gamma)}{\delta} \overline{I} \qquad (6)$$
Putting Eq. (6) into Eq. (3), we get;  

$$\left[\frac{r}{p} \overline{S} - \frac{(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\delta}\right] \overline{I} = 0 \qquad (7)$$

$$\overline{I} = 0 \text{ gives; } \overline{S} = \frac{\gamma p}{\gamma + \theta}, \ \overline{E} = 0, \text{ and } \overline{R} = \frac{\theta p}{\gamma + \theta}$$
One steady state is:  

$$[S_1, 0, 0, R_1] = \left[\frac{\gamma p}{\gamma + \theta}, 0, 0, \frac{\theta p}{\gamma + \theta}\right]$$
From Eq. (7), we get:  $\overline{S} = \frac{P(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\tau \delta}$ 
Putting Eq. (8) into Eq. (2), we get  $\overline{I} = \frac{\delta \gamma p}{(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)} - \frac{P(\gamma + \theta)}{\tau}$ 
From Eq. (4),  $E = \frac{\gamma p}{\delta + \gamma} - \frac{P(\gamma + \theta)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\tau \delta}$ 
From Eq. (5), we get  $\overline{R} = \frac{\delta p}{\delta + \gamma} - \frac{P(\gamma + \theta)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\gamma \tau} + \frac{\theta P(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\tau \delta \gamma}$ 
This gives us another steady state:  $[S_2, E_2, I_2, R_2] = \left[\frac{P(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\tau \delta}, \frac{\gamma p}{\delta + \gamma} - \frac{P(\gamma + \theta)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\tau \delta}, \frac{\delta \gamma p}{\delta + \gamma} - \frac{P(\gamma + \theta)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\gamma \tau} + \frac{\theta P(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)}{\tau \delta \gamma}\right]$ 

#### **Basic Reproduction Number**

Lemma 2.1 The basic reproduction number for the model Eq. (1) is:

$$\begin{split} R_0 &= \sqrt{\frac{\tau\delta}{(\delta+\gamma)(\alpha_1+\alpha_2+\mu+\gamma)}} \\ \hline \mathbf{Proof} \\ \mathbf{From the linearized infection subsystem of Eq. (1), we get;} \\ \frac{dE}{dt} &= \tau \mathbf{I} - (\delta+\gamma) \mathbf{E} \\ \frac{dI}{dt} &= \delta E - (\alpha_1 + \alpha_2 + \mu + \gamma) \\ \text{This gives rise to the transmission matrix;} \\ Q &= \begin{bmatrix} 0 & \tau \\ \delta & 0 \end{bmatrix} \text{ and the transmission matrix; } T = \begin{bmatrix} -(\delta+\gamma) & 0 \\ 0 & -(\alpha_1+\alpha_2+\mu+\gamma) \end{bmatrix} \\ \text{The next generation matrix is given by:} \\ X &= -QT^{-1} = \begin{bmatrix} 0 & \tau \\ \delta & 0 \end{bmatrix} \begin{bmatrix} \frac{1}{\delta+\gamma} & 0 \\ 0 & \frac{1}{\alpha_1+\alpha_2+\mu+\gamma} \end{bmatrix}, \text{ from which we compute } R_0: \\ R_0 &= \rho(X) = \frac{1}{2}(trace X + \sqrt{(trace X)^2 - 4 \det(X)} = \sqrt{\frac{\tau\delta}{(\delta+\gamma)(\alpha_1+\alpha_2+\mu+\gamma)}}, \text{ where } \rho \text{ is } \end{split}$$

the spectral radius.

#### 3. Results and Discussion

**Local Stability Analysis. Theorem 2.2** The disease-free equilibrium of the SEIR model is locally asymptotically stable when  $R_0 < 1$ 

**<u>Proof</u>** From the system in Eq. (1), we get the Jacobian matrix:

$$J = \begin{bmatrix} -(\gamma + \frac{\tau I}{p}) & 0 & \frac{-\tau S}{p} & 0\\ \frac{\tau \overline{I}}{p} & -(\delta + \gamma) & \frac{\tau \overline{S}}{p} & 0\\ 0 & \delta & -(\alpha_1 + \alpha_2 + \mu + \gamma) & 0\\ \theta & 0 & \alpha_1 + \alpha_2 + \mu + \gamma & -\gamma \end{bmatrix}$$

At the steady state: 
$$[S_1, 0, 0, R_1]$$
:  

$$J = \begin{bmatrix} -u & 0 & -\frac{\tau y}{u} & 0 \\ 0 & -w & \frac{\tau y}{u} & 0 \\ \theta & 0 & v & -\gamma \end{bmatrix}$$
Where,  $u = \gamma + \theta$ ,  $v = \alpha_1 + \alpha_2 + \mu + \gamma$  and  $w = \delta + \gamma$   

$$J - \lambda I = \begin{bmatrix} -u - \lambda & 0 & -\frac{\tau y}{u} & 0 \\ 0 & -w & \frac{\tau y}{u} & 0 \\ 0 & \delta & -v & 0 \\ \theta & 0 & v & -\gamma \end{bmatrix}$$

$$|J - \lambda I| = 0 \Rightarrow \begin{bmatrix} -u - \lambda & 0 & -\frac{\tau y}{u} & 0 \\ 0 & -w - \lambda & \frac{\tau y}{u} & 0 \\ 0 & \delta & -v - \lambda & 0 \\ \theta & 0 & v & -\gamma - \lambda \end{bmatrix} = 0$$

$$(-u - \lambda) \begin{bmatrix} -w - \lambda & \frac{\tau y}{u} & 0 \\ 0 & \delta & -v - \lambda & 0 \\ 0 & v & -\gamma - \lambda \end{bmatrix} \begin{bmatrix} -\frac{\tau y}{u} & 0 \\ 0 & \delta & 0 \\ 0 & v & -\gamma - \lambda \end{bmatrix} = 0$$
This gives us:  $(-u - \lambda)(-\gamma - \lambda) [(-w - \lambda)(-v - \lambda) - \frac{\delta \tau \gamma}{u}] = 0$ 
 $(-u - \lambda)(-v - \lambda) - \frac{\delta \tau \gamma}{u} = 0 \Rightarrow \lambda^2 + \lambda(v + w) + vw - \frac{\delta \tau \gamma}{u} = 0$ 
Let  $f(\lambda) = \lambda^2 + \lambda(v + w) + vw - \frac{\delta \tau \gamma}{u}$ ,
Since  $\lambda > 0$ , then by Descartes' rule [16], there are two negative real eigenvalues if  $vw - \frac{\delta \tau \gamma}{u} > 0$ 

$$vw - \frac{\delta\tau\gamma}{u} > 0 \Rightarrow \frac{\delta\tau\gamma}{(\gamma + \theta)(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)} < 1$$
  
$$\frac{\delta\tau\gamma}{(\nu + \theta)(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)} < \frac{\delta\tau}{(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma)} < 1 \Rightarrow R_0 < 1$$

 $(\gamma + \theta)(\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma) = (\delta + \gamma)(\alpha_1 + \alpha_2 + \mu + \gamma) = \Gamma \rightarrow R_0 < \Gamma$  **Theorem 2.3** The endemic equilibrium of the SEIR model is locally asymptotically stable if  $R_0 > 1$ **Proof** At the equilibrium point  $[S_2, E_2, I_2, R_2]$ , the Jacobian matrix is given by:

$$J = \begin{bmatrix} -\frac{i\delta \gamma}{vw} & 0 & -\frac{iw}{\delta} & 0\\ \frac{\tau\delta\gamma}{vw} - u & -w & \frac{vw}{\delta} & 0\\ 0 & \delta & -v & 0\\ \theta & 0 & v & -\gamma \end{bmatrix}$$

$$J - \lambda I = \begin{bmatrix} -\frac{\tau\delta\gamma}{vw} - \lambda & 0 & -\frac{vw}{\delta} & 0\\ \frac{\tau\delta\gamma}{vw} - u & -w - \lambda & \frac{vw}{\delta} & 0\\ 0 & \delta & -v - \lambda & 0\\ \theta & 0 & v & -\gamma - \lambda \end{bmatrix}$$
From  $|J - \lambda I| = \begin{bmatrix} -\frac{\tau\delta\gamma}{vw} - \lambda & 0 & -\frac{vw}{\delta} & 0\\ 0 & \delta & -v - \lambda & 0\\ -\frac{\tau\delta\gamma}{vw} - u & -w - \lambda & \frac{vw}{\delta} & 0\\ 0 & \delta & -v - \lambda & 0\\ -\frac{\tau\delta\gamma}{vw} - u & -w - \lambda & \frac{vw}{\delta} & 0\\ 0 & \delta & -v - \lambda & 0\\ -\frac{\tau\delta\gamma}{vw} - u & -w - \lambda & \frac{vw}{\delta} & 0\\ 0 & 0 & v & -\gamma - \lambda \end{bmatrix} = 0, \text{ we get:}$ 

$$(-\gamma - \lambda) \left\{ (-w - \lambda)(-v - \lambda) \left( -\frac{\tau\delta\gamma}{vw} - \lambda \right) + vw(\lambda + u) \right\} = 0$$
We have:  $(-\gamma - \lambda) = 0 \Rightarrow \gamma = -\lambda$ 

Edet and Etukudo

J. of NAMP

$$\begin{aligned} (-w-\lambda)(-v-\lambda)\left(-\frac{\tau\delta\gamma}{vw}-\lambda\right)+vw(\lambda+u)&=0 \ \Rightarrow -\lambda^{3}-\lambda^{2}\left(v+w+\frac{\tau\delta\gamma}{vw}\right)-\lambda\left(vw+\frac{\tau\delta\gamma}{w}+\frac{\tau\delta\gamma}{v}\right)+vw(\lambda+u)-\tau\delta\gamma\\ \tau\delta\gamma&=0\\ \text{Let }f(\lambda)&=-\lambda^{3}-\lambda^{2}\left(v+w+\frac{\tau\delta\gamma}{vw}\right)-\lambda\left(vw+\frac{\tau\delta\gamma}{w}+\frac{\tau\delta\gamma}{v}\right)+vw(\lambda+u)-\tau\delta\gamma&=0, \text{ also, let }\\ f(-\lambda)&=\lambda^{3}-\lambda^{2}\left(v+w+\frac{\tau\delta\gamma}{vw}\right)+\lambda\left(vw+\frac{\tau\delta\gamma}{w}+\frac{\tau\delta\gamma}{v}\right)+vw(\lambda+u)-\tau\delta\gamma&=0, \text{ By Descartes' rule, the eigenvalues will be negative if }vw(\lambda+u)-\tau\delta\gamma&<0\\ vw(\lambda+u)-\tau\delta\gamma&<0 \ \Rightarrow vw(\lambda+u)<\tau\delta\gamma&\Rightarrow1<\frac{\tau\delta\gamma}{vw(\lambda+u)}\\ 1&<\frac{\tau\delta\gamma}{(\delta+\gamma)(\lambda+\gamma+\theta)(\alpha_{1}+\alpha_{2}+\mu+\gamma)}<\frac{\tau\delta}{(\delta+\gamma)(\alpha_{1}+\alpha_{2}+\mu+\gamma)}&\Rightarrow1<\frac{\tau\delta}{(\delta+\gamma)(\alpha_{1}+\alpha_{2}+\mu+\gamma)}>1 \ or \ R_{0}>1\end{aligned}$$

#### **Global Stability Analysis**

**Theorem 2.5** If  $R_0 > 1$  and  $\tau < (\gamma + \delta)$ , then the disease-free equilibrium point is globally asymptotically stable in the domain:  $\mathcal{U}_{0} = \left\{ \left( S, E, I, R \right) \in \mathbb{R}_{+}^{4} : S < \frac{P}{\tau} (\gamma + \delta) \right\}$ <u>**Proof**</u> Define a Lyapunov function W = E. We have that:  $\frac{dW}{dt} = \left[ \frac{\tau}{P} S - (\delta + \gamma) \right] E \leq 0 \text{ if } S < \frac{P}{\tau} (\delta + \gamma), \text{ that is, } \frac{dL}{dt} \leq 0 \text{ in the domain } \mathcal{U}_{0}.$ For the positive definite function W, the derivative  $\frac{dW}{dt}$  is negative semi-definite in  $\mathfrak{V}_0$ . Now we consider the set where  $\frac{dW}{dt} = 0$ . Let  $\Psi = \left\{ (S, E, I, R) \in \mathfrak{V}_0 : \frac{dW}{dt} = 0 \right\} = \{ (S, E, I, R) \in \mathfrak{V}_0 : E = 0 \}$ Let M be the largest invariant set in  $\mathfrak{V}_0$ . Then in  $\mathfrak{V}_0$ , we have:  $\frac{dS}{dt} = \gamma(P - S) - \theta S$  $\frac{dI}{dt} = \delta I - \nu I$ (9) (10)dt dR  $= vI + \theta S - \gamma R$ (11)From Eq. (1), we have  $R \to \frac{\theta P}{\gamma + \theta}$  as  $t \to \infty$ . From Eq. (10), if  $\delta < v$ , we have  $I \to 0$  as  $t \to \infty$ . From Eq. (9), we have  $S \to \frac{\gamma P}{\gamma + \theta}$  as  $t \to \infty$ . The steady state is globally asymptotically stable if  $\delta < v \Leftrightarrow \frac{\delta}{\alpha_1 + \alpha_2 + \mu + \gamma} < 1 \Rightarrow \frac{\tau \delta}{(\gamma + \delta)(\alpha_1 + \alpha_2 + \mu + \gamma)} < \frac{\delta}{\alpha_1 + \alpha_2 + \mu + \gamma} < 1$  if  $\tau < \gamma + \delta$ . **Theorem 2.6** The endemic steady state is globally asymptotically stable in the domain:  $\mathbb{O}_1 = \left\{ (S, E, I, Q, R) \in \mathbb{R}^4_+ : 1 < \frac{E_2}{E} < \frac{I_2}{I} < \frac{R_2}{R} < \frac{S_2}{S} \right\}$  **Proof** Consider a Lyapunov function M defined as follows:  $M = \int_{S_2}^{S} \frac{S - S_2}{S} dS + \int_{E_2}^{E} \frac{E - E_2}{E} dE + \int_{I_2}^{I} \frac{I - I_2}{I} dI + \int_{R_2}^{R} \frac{R - R_2}{R} dR$ 

We have;

$$\frac{dM}{dt} = \left(\frac{S-S_2}{S}\right)\frac{dS}{dt} + \left(\frac{E-E_2}{E}\right)\frac{dE}{dt} + \left(\frac{I-I_2}{I}\right)\frac{dI}{dt} + \left(\frac{R-R_2}{R}\right)\frac{dR}{dt} = (S-S_2)\left(\frac{\gamma P}{S} - \frac{\gamma P}{S_2} + \frac{\tau I_2}{P} - \frac{\tau I}{P}\right) + (E-E_2)\left(\frac{\tau SI}{PE} - \frac{\tau S_2 I_2}{PE}\right) + (I-I_2)\left(\frac{\delta E}{I} - \frac{\delta E_2}{I_2}\right) + (R-R_2)\left(\frac{wI}{R} - \frac{wI_2}{R_2} + \frac{\theta S}{R} - \frac{\theta S_2}{R_2}\right) = (S-S_2)\left(\frac{\gamma P(S_2-S)}{SS_2} + \frac{\tau (I_2-I)}{P}\right) + (E-E_2)\left(\frac{\tau (E_2SI-S_2I_2E)}{EE_2}\right) + (I-I_2)\left(\frac{\delta (I_2E-IE_2)}{II_2}\right) + (R-R_2)\left(\frac{w(IR_2-I_2R)}{RR_2} + \frac{\theta (SR_2-S_2R)}{RR_2}\right) = -\frac{\gamma P(S_2-S)^2}{SS_2} - \frac{\tau (S_2-S)(I_2-I)}{P} - \frac{\tau (E_2-E)(SIE_2-S_2I_2E)}{EE_2} - \frac{\delta (I_2-I)(I_2E-IE_2)}{II_2} - \frac{w(R_2-R)(IR_2-I_2R)}{RR_2} - \frac{\theta (R_2-R)(SR_2-S_2R)}{RR_2}$$
From the region:  $1 < \frac{E_2}{E_2} < \frac{I_2}{I_2} < \frac{S_2}{R_2} < \frac{S_2}{R_2}$  we have:  $IS = SI < I(S - S) = FS = SE < F(S - S) = FI = IE$ 

From the region:  $1 < \frac{L_2}{E} < \frac{I_2}{I} < \frac{R_2}{S} < \frac{S_2}{S}$ , we have;  $IS_2 - SI_2 < I(S_2 - S)$ ,  $ES_2 - SE_2 < E(S_2 - S)$ ,  $EI_2 - IE_2 < E(I_2 - I)$ ,  $IR_2 - RI_2 < I(R_2 - R)$ ,  $SR_2 - RS_2 < S(R_2 - R)$ , and  $SI < S_2I_2$ .

Hence, we get;

dМ	$\sim \frac{\gamma P(S_2-S)^2}{2}$	$\frac{\tau(S_2-S)(I_2-I)}{\tau(S_2-S)(I_2-I)}$	$\tau S_2$	$_{2}I_{2}(E_{2}-E)^{2}$	$\delta E(I_2-I)^2$	$WI(R_2-R)^2$	$\theta S(R_2-R)^2$	- 0
dt	SS <sub>2</sub>	Р	P	$EE_2$	II <sub>2</sub>	RR <sub>2</sub>	RR <sub>2</sub>	< 0

#### Numerical Simulation.

Scilab plot of the SEIR model for  $R_0 < 1$  [Fig. 1] Define a solution to the system in Eq. (1) for the parameter values;  $\gamma = 0.000038$ ,  $\tau = 0.2$ ,  $\delta = 0.33$ ,  $\alpha_1 = 0.07143$ ,  $\alpha_2 = 0.03175$ ,  $\delta = 2.08$ ,  $\theta = 0.00556$  subject to the initial conditions: s(0) = 0.7, e(0) = 0.15, i(0) = 0.1, r(0) = 0.05, where  $s = \frac{s}{N}$ ,  $e = \frac{E}{N}$ ,  $i = \frac{I}{N}$ ,  $q = \frac{Q}{N}$ ,  $r = \frac{R}{N}$ . The population N is taken to be 1000. Scilab Code: function ydot=SEIRdmodel(t, y) ydot=[p-t\*y(1)\*y(3)-p\*y(1)-s\*y(1);t\*y(1)\*y(3)-(d+p)\*y(2);d\*y(2)-(a1+a2+u+p)\*y(3);(a1+a2+u+p)\*y(3)+s\*y(1)p\*y(4)] endfunction p=0.000038; t=0.3; d=0.33; a1=0.07143; a2=0.03175; u=2.08; s=0.0056; y0=[0.7;0.15;0.1;0.05]'; t0=0; t=0:7:365; sol=ode([0.7;0.15;0.1;0.05],t0,t,SEIRdmodel); plot(t,sol(1,:),'k-o-',t,sol(2,:),'k++-',t,sol(3,:),'k-.',t,sol(4,:),'k-x-') title("2D Plot of SEIR model of COVID-19 with rate of infection =0.3", "fontsize",3) hl=legend(['s';'e';'i';'r']);



Fig 1. Scilab plot of the SEIR Model for  $R_0 < 1$ 

Fig 2. Scilab plot of the SEIR Model for  $R_0 > 1$ 



Scilab plot of the SEIR model for  $R_0 > 1$ . [Fig. 2] Define a solution to the system in Eq. (1) for the parameter values;  $\gamma = 0.000038$ ,  $\tau = 12 \ \delta = 0.33$ ,  $\alpha_1 = 0.07143$ ,  $\alpha_2 = 0.03175$ ,  $\delta = 2.08$ ,  $\theta = 0.00556$  subject to the initial conditions: s(0) = 0.7, e(0) = 0.15, i(0) = 0.1, r(0) = 0.05, where  $s = \frac{s}{N}$ ,  $e = \frac{E}{N}$ ,  $i = \frac{I}{N}$ ,  $q = \frac{Q}{N}$ ,  $r = \frac{R}{N}$ . The population N is taken to be 1000.

# Scilab Code: function ydot=SEIRdmodel(t, y)

ydot=[p-t\*y(1)\*y(3)-p\*y(1)-s\*y(1);t\*y(1)\*y(3)-(d+p)\*y(2);d\*y(2)-(a1+a2+u+p)\*y(3);(a1+a2+u+p)\*y(3)+s\*y(1)-p\*y(4)]endfunction p=0.000038; t=12; d=0.33: a1=0.07143; a2=0.03175; u=2.08; s=0.0056; y0=[0.7;0.15;0.1;0.05]'; t0=0; t=0:7:365; sol=ode([0.7;0.15;0.1;0.05],t0,t,SEIRdmodel); plot(t,sol(1,:),'k-o-',t,sol(2,:),'k++-',t,sol(3,:),'k-.',t,sol(4,:),'k-x-') title("2D Plot of SEIR model of COVID-19 with rate of infection =12", "fontsize", 3) hl=legend(['s';'e';'i';'r']);

#### **Discussion of Results**

We have formulated an SEIR model with a vaccination parameter for the transmission dynamics of COVID-19. We studied the stability of the equilibrium points of the system in Eq. (1). The local stability of the disease-free equilibrium implies that if a small number of infected individuals are introduced into the population, after a short time the system will converge to the disease-free equilibrium point (that is, the disease will die out of the population). For the endemic equilibrium, the local stability implies that if a small number of infected individuals are introduced into the population, then after a short time, the system will converge back to the endemic equilibrium point (that is, the disease will die out). The global stability of the disease-free equilibrium point implies that whatever the number of the infected individuals introduced into the population, in the long run, the disease will eventually die out of the population. On the other hand, the global stability of the endemic equilibrium implies that in the long run, the disease will become endemic or will continue to prevail in the population, irrespective of the number of infected individuals introduced into the population,

The parameters of the model were estimated and the model was solved numerically using the scilab software. The result of the simulation shows that, if the basic reproduction number is less than one, in a very short time individuals in the population are removed by death, recovery or vaccination and the disease eventually dies out of the population. The same trend is observed when the basic reproduction number is greater than one. This happens because of the vaccination parameter  $\theta$ .

#### 4. Conclusion

Based on the results of the study, it was concluded that the SEIR model with a vaccination parameter could be used as a reference model for the spread of COVID-19 in a population. Analyses of the model provides an overview of global and local stability in the spread of COVID-19 depending upon the value of the basic reproduction number.

The simulation results provide a predictive picture of the short-term and long-term behavior of

the disease outbreak, and also shows that the presence of the vaccination parameter causes the disease to die out of the population regardless of the value of the basic reproduction number.

#### 5. Acknowledgement

The author is very grateful to the anonymous referee and handling editor for their careful reading and checking of details.

#### References

- Mallapaty, S., Callaway, E., Kozlov, M., Ledford, H., Pickrell, J., Van Noorden, R. (2021). "How COVID vaccine shaped 2021 in eight powerful charts". Nature. 600 (7890): 580-
  - 583. Bibcode:2021Natur.600..580M. doi:10.1038/d41586-021-03686-x. PMID 34916666. S2CID 245262732
- [2] Beaumont, P. (2020). "Covid-19 vaccine: who are countries prioritizing for first doses?". The Guardian. ISSN 0261-3077. Retrieved 26 December 2020.
- [3] Richie, H., Ortiz-Ospina, E., Beltekian, D., Methieu, E., Hasell, J., Macdonald, B., et al. (2021).
   "Coronavirus (COVID-19) Vaccinations Statistics and Research". Our World in Data. Retrieved 7 February 2021.
- [4] Mullard, A. (2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. S2CID
- [5] So, A. D., Woo, J. (2020). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". BMJ. 371: m4750. doi:10.1136/bmj.m4750. PMC 7735431. PMID 33323376
- [6] Kahn, R., Holmdahl, I. Reddy, S., Jernigan, J., Mina, M.J., Slayton, R. B., (2021). Mathematical Modeling to Inform Vaccination Strategies and Testing Approaches for Coronavirus Disease 2019
- [7] Gokbulut, N., Kaymakamzade, B., Sanlidag, T., Hincal, E., (2021) Mathematical modelling of Covid-19 with the effect of vaccine, AIP Conference Proceedings **2325**,020065 https://doi.org/10.1063/5.0040301
- [8] Yavuz, M., Coşar, F., Günay, F. and Özdemir, F. (2021) A New Mathematical Modeling of the COVID-19 Pandemic Including the Vaccination Campaign. Open Journal of Modelling and Simulation, 9, 299-321. doi: 10.4236/ojmsi.2021.93020
- [9] Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L., Keeling, M. J., (2021), Vaccination and non-pharmaceutical interventions for COVID-19: A mathematical modelling study, The Lancet Infectious Diseases, Volume 21, Issue 6 Pages 793-802, ISSN 1473-3099
- [10] Diagne, M. L., Rwezaura, H. Tchoumi, S. Y., Tchuenche, J. M., (2021). A Mathematical Model of COVID-19 with Vaccination and Treatment. Comput MathMethods Med :1250129.
- [11] Universitat Pompeu Fabra Barcelona (2021). "A mathematical model to help optimize vaccine development." ScienceDaily. ScienceDaily. <www.sciencedaily.com/releases/2021/10/211027134956.htm>.
- [12] Roser, M., Rrtiz-Ospina, E. and Ritchie, H. (2013) "Life Expectancy". Published online at OurWorldInData.org. Retrieved from: 'https://ourworldindata.org/life-expectancy' [Online Resource]
- [13] Liu, Z., Magal, P., Seydi, O. and Webb, G. (2020). A COVID-19 epidemic model with latency period, Infectious Disease Modelling, 5:323-337 https://doi.org/10.1016/j.idm.2020.03.003
- [14] World Health Organization (WHO) (2020), Report of the WHO-China joint mission on coronavirus disease 2019 COVID-19)
- https://www,who.int/docs/default-source/coronavirus/who-china-joint-missionon-covid-19-final-pdf.(2019)
   [15] Caroline Tien (2021) "How long will COVID-19 Vaccine-Induced Immunity last?"
- www.verywellhealth.com/length-of-covid-19-vaccine-immunity-5094857
- [16] Haukkanen, P. (2011) On Descartes' rule of signs, Far East J. Math. Edu., 6(1): 21-28.